{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:59:49Z","timestamp":1771991989403,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1038\/s41440-023-01428-2","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:01:43Z","timestamp":1693904503000},"page":"2547-2550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Emerging association between KCNJ5 mutations and vascular failure in primary aldosteronism"],"prefix":"10.1038","volume":"46","author":[{"given":"Kota","family":"Jojima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"1428_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10\u201320.","journal-title":"Ann Intern Med"},{"key":"1428_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1428_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1210\/js.2018-00260","volume":"3","author":"M Yoshioka","year":"2018","unstructured":"Yoshioka M, Nakajima Y, Miyamoto T, Igarashi T, Sakamaki K, Akuzawa M, et al. Age-dependent progression of renal dysfunction after adrenalectomy for aldosterone-producing adenomas in Japan. J Endocr Soc. 2018;3:577\u201389.","journal-title":"J Endocr Soc"},{"key":"1428_CR4","doi-asserted-by":"publisher","first-page":"830130","DOI":"10.3389\/fendo.2022.830130","volume":"13","author":"BC Lee","year":"2022","unstructured":"Lee BC, Kang VJ, Pan CT, Huang JZ, Lin YL, Chang YY, et al. KCNJ5 somatic mutation is associated with higher aortic wall thickness and less calcification in patients with aldosterone-producing adenoma. Front Endocrinol (Lausanne). 2022;13:830130.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1428_CR5","doi-asserted-by":"publisher","first-page":"1061704","DOI":"10.3389\/fendo.2023.1061704","volume":"14","author":"YY Chang","year":"2023","unstructured":"Chang YY, Lee BC, Chen ZW, Tsai CH, Chang CC, Liao CW, et al. Cardiovascular and metabolic characters of KCNJ5 somatic mutations in primary aldosteronism. Front Endocrinol (Lausanne). 2023;14:1061704.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1428_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1161\/HYPERTENSIONAHA.120.15679","volume":"77","author":"YY Chang","year":"2021","unstructured":"Chang YY, Tsai CH, Peng SY, Chen ZW, Chang CC, Lee BC, et al. KCNJ5 somatic mutations in aldosterone-producing adenoma are associated with a worse baseline status and better recovery of left ventricular remodeling and diastolic function. Hypertension. 2021;77:114\u201325.","journal-title":"Hypertension"},{"key":"1428_CR7","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1097\/HJH.0000000000002948","volume":"39","author":"KM Chen","year":"2021","unstructured":"Chen KM, Chang YL, Wu TH, Lee BC, Chen PT, Liu KL, et al. Aldosterone-producing adenoma-harbouring KCNJ5 mutations is associated with lower prevalence of metabolic disorders and abdominal obesity. J Hypertens. 2021;39:2353\u201360.","journal-title":"J Hypertens"},{"key":"1428_CR8","doi-asserted-by":"publisher","unstructured":"Kishimoto S, Oki K, Maruhashi T, Kajikawa M, Mizobuchi A, Harada T, et al. KCNJ5 mutation is a predictor for recovery of endothelial function after adrenalectomy in patients with aldosterone-producing adenoma. Hypertens Res. 2023. https:\/\/doi.org\/10.1038\/s41440-023-01375-y.","DOI":"10.1038\/s41440-023-01375-y"},{"key":"1428_CR9","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1097\/01.hjh.0000249684.76296.4f","volume":"24","author":"T Inoue","year":"2006","unstructured":"Inoue T, Node K. Vascular failure: a new clinical entity for vascular disease. J Hypertens. 2006;24:2121\u201330.","journal-title":"J Hypertens"},{"key":"1428_CR10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.118.11554","volume":"72","author":"A Tanaka","year":"2018","unstructured":"Tanaka A, Tomiyama H, Maruhashi T, Matsuzawa Y, Miyoshi T, Kabutoya T, et al. Physiological diagnostic criteria for vascular failure. Hypertension. 2018;72:1060\u201371.","journal-title":"Hypertension"},{"key":"1428_CR11","doi-asserted-by":"publisher","first-page":"e013915","DOI":"10.1161\/JAHA.119.013915","volume":"9","author":"T Maruhashi","year":"2020","unstructured":"Maruhashi T, Kajikawa M, Kishimoto S, Hashimoto H, Takaeko Y, Yamaji T, et al. Diagnostic criteria of flow-mediated vasodilation for normal endothelial function and nitroglycerin-induced vasodilation for normal vascular smooth muscle function of the brachial artery. J Am Heart Assoc. 2020;9:e013915.","journal-title":"J Am Heart Assoc"},{"key":"1428_CR12","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","volume":"79","author":"F Buffolo","year":"2022","unstructured":"Buffolo F, Tetti M, Mulatero P, Monticone S. Aldosterone as a mediator of cardiovascular damage. Hypertension. 2022;79:1899\u2013911.","journal-title":"Hypertension"},{"key":"1428_CR13","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1210\/jc.2015-2752","volume":"100","author":"CH Chou","year":"2015","unstructured":"Chou CH, Chen YH, Hung CS, Chang YY, Tzeng YL, Wu XM, et al. Aldosterone impairs vascular smooth muscle function: from clinical to bench research. J Clin Endocrinol Metab. 2015;100:4339\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"1428_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1530\/EC-21-0057","volume":"10","author":"D Watanabe","year":"2021","unstructured":"Watanabe D, Morimoto S, Morishima N, Ichihara A. Clinical impacts of endothelium-dependent flow-mediated vasodilation assessment on primary aldosteronism. Endocr Connect. 2021;10:578\u201387.","journal-title":"Endocr Connect"},{"key":"1428_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jacasi.2023.03.010","volume":"3","author":"LC Chen","year":"2023","unstructured":"Chen LC, Huang WC, Peng KY, Chen YY, Li SC, Syed Mohammed Nazri SK, et al. Identifying KCNJ5 mutation in aldosterone-producing adenoma patients with baseline characteristics using machine learning technology. JACC Asia. 2023;3:664\u201375.","journal-title":"JACC Asia"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01428-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01428-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01428-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:06:55Z","timestamp":1699229215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01428-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1038\/s41440-023-01428-2","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"5 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KJ declares no conflicts of interest associated with this manuscript. AT has received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline, Takeda, Bristol Myers Squibb, and Novo Nordisk. KN has received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe, MSD, Novartis, Novo Nordisk, Ono, Otsuka, and Takeda; research grant from Asahi Kasei, Astellas, Boehringer Ingelheim Japan, Fuji, Mitsubishi Tanabe, Mochida, Novartis, and Teijin; scholarship from Bayer, Medtronic, and Teijin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}